Abstract 13089: Serum Soluble ST2 as a Biomarker for Detecting Heart Failure with a Normal Ejection Fraction in Hypertensive Patients

Yi-Chih Wang, Chih-Chieh Yu, Fu-Chun Chiu, Juey-Jen Hwang, Ling-Ping Lai, Chia-Ti Tsai, Jiunn-Lee Lin

研究成果: 雜誌貢獻文章

摘要

Background. Serum soluble ST2 is a novel diagnostic and prognostic marker for patients (pts) with heart failure (HF) and left ventricular (LV) systolic dysfunction. However, its application to HF with a normal LV ejection fraction (LVEF) (HFNEF) remains less studied.Method. Echocardiography, serum NT-proBNP and ST2 concentration were evaluated in 107 hypertensive pts (65±12 years, 57 male) with EF >50 %, serum creatinine <1.4 mg/dl and without significant valvular heart disease or active ischemia. Among them, 68 pts with HF signs/symptoms and mitral E/Ea (annular early diastolic velocity) > 8 were the HFNEF group, and the other 39 pts were as the control (Ctrl).Result. When compared to the Ctrl, pts with HFNEF were older (68±10 vs. 60±12 years, P <0.001), more female (54 vs. 33 %, P=0.036), and had greater left atrial diameter (38±5 vs. 35±6 mm, P=0.043), greater LV wall thickness, and more severe diastolic abnormality as expected. The serum level of NT-proBNP (262±470 vs. 71±53 pg/ml, p=0.025) and ST2 (18±8 vs. 12±5 ng/ml, p<0.001) were also higher in pts with HFNEF than in Ctrl. The area under the receiver-operating characteristic curve for ST2 was 0.80 (95 % CI, 0.70 to 0.89, P<0.001), better than that for NT-proBNP (area under the curve, 0.70; 95 % CI, 0.58 to 0.79, P<0.003) to detect HFNEF (figure). However, the NT-proBNP concentration increased much more significantly when the mitral E/Ea elevated (E/Ea >15: 650±874 vs. E/Ea 8-15: 163±214 pg/ml, p<0.001), but the serum ST2 remained unchanged even with a higher mitral E/Ea (E/Ea >15: 18±8 vs. E/Ea 8-15: 18±6 ng/ml, p=ns). After multivariate adjustment, the ST2 >13.5 ng/ml was independently associated with HFNEF in hypertensive pts (hazard ratio=2.5, 95 % CI=1.8-4.4; p<0.001).Conclusion. The data suggested serum ST2 measurement could serve as an independent biomarker for diagnostic aid of HFNEF in hypertensive pts. Addition of NT-proBNP to ST2 could provide more information regarding the severity of LV diastolic impairment.
原文繁體中文
頁(從 - 到)A13089
期刊Circulation
124
發行號Suppl 21
出版狀態已發佈 - 十一月 22 2011
對外發佈Yes

Keywords

  • Biomarkers
  • heart failure with normal ejection fraction
  • diastolic function
  • echocardiography

引用此文

Abstract 13089: Serum Soluble ST2 as a Biomarker for Detecting Heart Failure with a Normal Ejection Fraction in Hypertensive Patients. / Wang, Yi-Chih; Yu, Chih-Chieh; Chiu, Fu-Chun; Hwang, Juey-Jen; Lai, Ling-Ping; Tsai, Chia-Ti; Lin, Jiunn-Lee.

於: Circulation, 卷 124, 編號 Suppl 21, 22.11.2011, p. A13089.

研究成果: 雜誌貢獻文章

Wang, Y-C, Yu, C-C, Chiu, F-C, Hwang, J-J, Lai, L-P, Tsai, C-T & Lin, J-L 2011, 'Abstract 13089: Serum Soluble ST2 as a Biomarker for Detecting Heart Failure with a Normal Ejection Fraction in Hypertensive Patients', Circulation, 卷 124, 編號 Suppl 21, 頁 A13089.
Wang Y-C, Yu C-C, Chiu F-C, Hwang J-J, Lai L-P, Tsai C-T 等. Abstract 13089: Serum Soluble ST2 as a Biomarker for Detecting Heart Failure with a Normal Ejection Fraction in Hypertensive Patients. Circulation. 2011 11月 22;124(Suppl 21):A13089.
Wang, Yi-Chih ; Yu, Chih-Chieh ; Chiu, Fu-Chun ; Hwang, Juey-Jen ; Lai, Ling-Ping ; Tsai, Chia-Ti ; Lin, Jiunn-Lee. / Abstract 13089: Serum Soluble ST2 as a Biomarker for Detecting Heart Failure with a Normal Ejection Fraction in Hypertensive Patients. 於: Circulation. 2011 ; 卷 124, 編號 Suppl 21. 頁 A13089.
@article{79ff260a5a87428291b4603089a68b84,
title = "Abstract 13089: Serum Soluble ST2 as a Biomarker for Detecting Heart Failure with a Normal Ejection Fraction in Hypertensive Patients",
abstract = "Background. Serum soluble ST2 is a novel diagnostic and prognostic marker for patients (pts) with heart failure (HF) and left ventricular (LV) systolic dysfunction. However, its application to HF with a normal LV ejection fraction (LVEF) (HFNEF) remains less studied.Method. Echocardiography, serum NT-proBNP and ST2 concentration were evaluated in 107 hypertensive pts (65±12 years, 57 male) with EF >50 {\%}, serum creatinine <1.4 mg/dl and without significant valvular heart disease or active ischemia. Among them, 68 pts with HF signs/symptoms and mitral E/Ea (annular early diastolic velocity) > 8 were the HFNEF group, and the other 39 pts were as the control (Ctrl).Result. When compared to the Ctrl, pts with HFNEF were older (68±10 vs. 60±12 years, P <0.001), more female (54 vs. 33 {\%}, P=0.036), and had greater left atrial diameter (38±5 vs. 35±6 mm, P=0.043), greater LV wall thickness, and more severe diastolic abnormality as expected. The serum level of NT-proBNP (262±470 vs. 71±53 pg/ml, p=0.025) and ST2 (18±8 vs. 12±5 ng/ml, p<0.001) were also higher in pts with HFNEF than in Ctrl. The area under the receiver-operating characteristic curve for ST2 was 0.80 (95 {\%} CI, 0.70 to 0.89, P<0.001), better than that for NT-proBNP (area under the curve, 0.70; 95 {\%} CI, 0.58 to 0.79, P<0.003) to detect HFNEF (figure). However, the NT-proBNP concentration increased much more significantly when the mitral E/Ea elevated (E/Ea >15: 650±874 vs. E/Ea 8-15: 163±214 pg/ml, p<0.001), but the serum ST2 remained unchanged even with a higher mitral E/Ea (E/Ea >15: 18±8 vs. E/Ea 8-15: 18±6 ng/ml, p=ns). After multivariate adjustment, the ST2 >13.5 ng/ml was independently associated with HFNEF in hypertensive pts (hazard ratio=2.5, 95 {\%} CI=1.8-4.4; p<0.001).Conclusion. The data suggested serum ST2 measurement could serve as an independent biomarker for diagnostic aid of HFNEF in hypertensive pts. Addition of NT-proBNP to ST2 could provide more information regarding the severity of LV diastolic impairment.",
keywords = "Biomarkers, heart failure with normal ejection fraction, diastolic function, echocardiography",
author = "Yi-Chih Wang and Chih-Chieh Yu and Fu-Chun Chiu and Juey-Jen Hwang and Ling-Ping Lai and Chia-Ti Tsai and Jiunn-Lee Lin",
year = "2011",
month = "11",
day = "22",
language = "繁體中文",
volume = "124",
pages = "A13089",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "Suppl 21",

}

TY - JOUR

T1 - Abstract 13089: Serum Soluble ST2 as a Biomarker for Detecting Heart Failure with a Normal Ejection Fraction in Hypertensive Patients

AU - Wang, Yi-Chih

AU - Yu, Chih-Chieh

AU - Chiu, Fu-Chun

AU - Hwang, Juey-Jen

AU - Lai, Ling-Ping

AU - Tsai, Chia-Ti

AU - Lin, Jiunn-Lee

PY - 2011/11/22

Y1 - 2011/11/22

N2 - Background. Serum soluble ST2 is a novel diagnostic and prognostic marker for patients (pts) with heart failure (HF) and left ventricular (LV) systolic dysfunction. However, its application to HF with a normal LV ejection fraction (LVEF) (HFNEF) remains less studied.Method. Echocardiography, serum NT-proBNP and ST2 concentration were evaluated in 107 hypertensive pts (65±12 years, 57 male) with EF >50 %, serum creatinine <1.4 mg/dl and without significant valvular heart disease or active ischemia. Among them, 68 pts with HF signs/symptoms and mitral E/Ea (annular early diastolic velocity) > 8 were the HFNEF group, and the other 39 pts were as the control (Ctrl).Result. When compared to the Ctrl, pts with HFNEF were older (68±10 vs. 60±12 years, P <0.001), more female (54 vs. 33 %, P=0.036), and had greater left atrial diameter (38±5 vs. 35±6 mm, P=0.043), greater LV wall thickness, and more severe diastolic abnormality as expected. The serum level of NT-proBNP (262±470 vs. 71±53 pg/ml, p=0.025) and ST2 (18±8 vs. 12±5 ng/ml, p<0.001) were also higher in pts with HFNEF than in Ctrl. The area under the receiver-operating characteristic curve for ST2 was 0.80 (95 % CI, 0.70 to 0.89, P<0.001), better than that for NT-proBNP (area under the curve, 0.70; 95 % CI, 0.58 to 0.79, P<0.003) to detect HFNEF (figure). However, the NT-proBNP concentration increased much more significantly when the mitral E/Ea elevated (E/Ea >15: 650±874 vs. E/Ea 8-15: 163±214 pg/ml, p<0.001), but the serum ST2 remained unchanged even with a higher mitral E/Ea (E/Ea >15: 18±8 vs. E/Ea 8-15: 18±6 ng/ml, p=ns). After multivariate adjustment, the ST2 >13.5 ng/ml was independently associated with HFNEF in hypertensive pts (hazard ratio=2.5, 95 % CI=1.8-4.4; p<0.001).Conclusion. The data suggested serum ST2 measurement could serve as an independent biomarker for diagnostic aid of HFNEF in hypertensive pts. Addition of NT-proBNP to ST2 could provide more information regarding the severity of LV diastolic impairment.

AB - Background. Serum soluble ST2 is a novel diagnostic and prognostic marker for patients (pts) with heart failure (HF) and left ventricular (LV) systolic dysfunction. However, its application to HF with a normal LV ejection fraction (LVEF) (HFNEF) remains less studied.Method. Echocardiography, serum NT-proBNP and ST2 concentration were evaluated in 107 hypertensive pts (65±12 years, 57 male) with EF >50 %, serum creatinine <1.4 mg/dl and without significant valvular heart disease or active ischemia. Among them, 68 pts with HF signs/symptoms and mitral E/Ea (annular early diastolic velocity) > 8 were the HFNEF group, and the other 39 pts were as the control (Ctrl).Result. When compared to the Ctrl, pts with HFNEF were older (68±10 vs. 60±12 years, P <0.001), more female (54 vs. 33 %, P=0.036), and had greater left atrial diameter (38±5 vs. 35±6 mm, P=0.043), greater LV wall thickness, and more severe diastolic abnormality as expected. The serum level of NT-proBNP (262±470 vs. 71±53 pg/ml, p=0.025) and ST2 (18±8 vs. 12±5 ng/ml, p<0.001) were also higher in pts with HFNEF than in Ctrl. The area under the receiver-operating characteristic curve for ST2 was 0.80 (95 % CI, 0.70 to 0.89, P<0.001), better than that for NT-proBNP (area under the curve, 0.70; 95 % CI, 0.58 to 0.79, P<0.003) to detect HFNEF (figure). However, the NT-proBNP concentration increased much more significantly when the mitral E/Ea elevated (E/Ea >15: 650±874 vs. E/Ea 8-15: 163±214 pg/ml, p<0.001), but the serum ST2 remained unchanged even with a higher mitral E/Ea (E/Ea >15: 18±8 vs. E/Ea 8-15: 18±6 ng/ml, p=ns). After multivariate adjustment, the ST2 >13.5 ng/ml was independently associated with HFNEF in hypertensive pts (hazard ratio=2.5, 95 % CI=1.8-4.4; p<0.001).Conclusion. The data suggested serum ST2 measurement could serve as an independent biomarker for diagnostic aid of HFNEF in hypertensive pts. Addition of NT-proBNP to ST2 could provide more information regarding the severity of LV diastolic impairment.

KW - Biomarkers

KW - heart failure with normal ejection fraction

KW - diastolic function

KW - echocardiography

M3 - 文章

VL - 124

SP - A13089

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - Suppl 21

ER -